natgillin/translations-raw huggingface dataset:
This benefit was mostly driven by the statistically significant reduction in the incidence of MI [287 (4.6%) in the clopidogrel treated group and 363 (5.8%) in the placebo treated group]. 
Ta korist je bila v glavnem zaradi statistično pomembnega zmanjšanja incidence MI [287 (4,6 %) v skupini, zdravljeni s klopidogrelom, in 363 (5,8 %) v skupini s placebom].
CYP2C8 substrate medicinal products: Clopidogrel has been shown to increase repaglinide exposure in healthy volunteers. 
Zdravila, ki so substrati CYP2C8: Klopidogrel je pri zdravih prostovoljcih povečal izpostavljenost repaglinida.
• if you have kidney or liver disease. 
• če imate ledvične ali jetrne bolezni;
If you think any of these apply to you, or if you are in any doubt at all, consult your doctor before taking Clopidogrel Mylan. 
Če menite, da se karkoli od navedenega nanaša na vas, ali če ste kakorkoli v dvomih, se posvetujte z zdravnikom, preden vzamete Klopidogrel Mylan.
Medicinal products associated with bleeding risk: There is an increased risk of bleeding due to the potential additive effect. 
Zdravila, povezana s tveganjem pojava krvavitev: Zaradi potencialno aditivnega učinka je povečano tveganje pojava krvavitev.
The clinically relevant adverse reactions observed in the CAPRIE, CURE, CLARITY, COMMIT and ACTIVE-A studies are discussed below. 
Klinično pomembni neželeni učinki, zabeleženi v študijah CAPRIE, CURE, CLARITY in COMMIT in ACTIVE-A, so predstavljeni spodaj.
Apart from the specific medicinal product interaction information described above, interaction studies with clopidogrel and some medicinal products commonly administered in patients with atherothrombotic disease have not been performed. 
Razen zgoraj navedenih podatkov o specifičnih interakcijah z zdravili, študij o inetrakcijah klopidogrela z nekaterimi drugimi zdravili, ki jih bolniki z aterotrombotično boleznijo pogosto uporabljajo, niso izvedli.
D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT 
D. POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO
What Clopidogrel Mylan is and what it is used for 2. 
Kaj je zdravilo Klopidogrel Mylan in za kaj ga uporabljamo 2.
Patients with a confirmed diagnosis of acquired haemophilia should be managed and treated by specialists, and clopidogrel should be discontinued 
Bolnike s potrjeno diagnozo pridobljene hemofilije morajo obravnavati in zdraviti zdravniki specialisti, zdravljenje s klopidogrelom pa je treba prekiniti.
If you have experienced severe chest pain (unstable angina or heart attack), you may be prescribed Clopidogrel Mylan in combination with acetylsalicylic acid, a substance present in many medicines used to relieve pain and lower fever. 
Če ste doživeli hudo bolečino v prsih (nestabilna angina pektoris ali srčni napad), so vam morda predpisali zdravilo Klopidogrel Mylan v kombinaciji z acetilsalicilno kislino, učinkovino, ki je prisotna v številnih zdravilih, ki se uporabljajo za lajšanje bolečine in zniževanje zvišane telesne temperature.
In CURE, there was no excess in major bleeds with clopidogrel plus ASA within 7 days after coronary bypass graft surgery in patients who stopped therapy more than five days prior to surgery. 
V študiji CURE število velikih krvavitev s klopidogrelom in ASA ni bilo prekoračeno v sedmih dneh po koronarni premostitveni operaciji pri bolnikih, ki so zdravljenje prekinili več kot pet dni pred kirurškim posegom.
The CYP2C19*2 and CYP2C19*3 alleles account for the majority of reduced function alleles in Caucasian (85%) and Asian (99%) poor metabolisers. 
Na račun alelov CYP2C19*2 in CYP2C19*3 gre večina alelov z zmanjšanim delovanjem pri Kavkazijcih (85 %) in pri Azijcih (99 %), ki so slabi metabolizatorji.
• Adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. 
• Odraslih bolnikih z miokardnim infarktom (od nekaj dni do manj kot 35 dni), ishemično kapjo (od 7 dni do manj kot 6 mesecev) ali dokazano periferno arterijsko boleznijo.
The safety and efficacy of clopidogrel have been evaluated in 5 double-blind studies involving over 88,000 patients: the CAPRIE study, a comparison of clopidogrel to ASA, and the CURE, CLARITY, COMMIT and ACTIVE-A studies comparing clopidogrel to placebo, both medicinal products given in combination with ASA and other standard therapy. 
Varnost in učinkovitost klopidogrela so vrednotili v petih dvojno slepih študijah, v katere je bilo vključenih več kot 88.000 bolnikov: študija CAPRIE je obsegala primerjavo klopidogrela in ASA, v študijah CURE, CLARITY, COMMIT in ACIVE-A pa so primerjali klopidogrel s placebom; oboje pa so bolniki dobivali v kombinaciji z ASA in drugo standardno terapijo.
In CURE, 823 (6.6%) patients received concomitant GPIIb/IIIa receptor antagonist therapy. 
V študiji CURE je 823 (6,6 %) bolnikov sočasno prejemalo terapijo z antagonisti receptorjev glikoproteinov IIb/IIIa.
In addition to clinical studies experience, adverse reactions have been spontaneously reported. 
Poleg neželenih učinkov v kliničnih študijah, so bili neželeni učinki prijavljeni tudi spontano.
The most common side effect reported with Clopidogrel Mylan is bleeding. 
Najpogostejši neželeni učinek o katerem so poročali med zdravljenjem z zdravilom Klopidogrel Mylan je krvavitev.
What Clopidogrel Mylan looks like and contents of the pack The film-coated tablets are pink, round and biconvex. 
Izgled zdravila Klopidogrel Mylan in vsebina pakiranja Filmsko obložente tablete so rožnate, okrogle in bikonvensne.
The benefit of the combination of clopidogrel with ASA beyond four weeks has not been studied in this setting (see section 5.1). 
Koristnosti zdravljenja s kombinacijo klopidrogela in ASA, ki bi bilo daljše od štirih tednov, v tem okviru niso preučevali (glejte poglavje 5.1).
If you become pregnant while taking Clopidogrel Mylan, consult your doctor immediately as it is recommended not to take clopidogrel while you are pregnant. 
Če med zdravljenjem z zdravilom Klopidogrel Mylan zanosite, se takoj posvetujte z zdravnikom, saj jemanje klopidogrela med nosečnostjo ni priporočljivo.
Driving and using machines Clopidogrel Mylan is unlikely to affect your ability to drive or to use machines. 
Vpliv na sposobnost upravljanja vozil in strojev Ni verjetno, da bi zdravilo Klopidogrel Mylan vplivalo na vašo sposobnost za vožnjo ali upravljanje strojev.
If you take more Clopidogrel Mylan than you should Contact your doctor or the nearest hospital emergency department because of the increased risk of bleeding. 
Če ste vzeli večji odmerek zdravila Klopidogrel Mylan, kot bi smeli Zaradi povečanega tveganja za krvavitev se posvetujte z zdravnikom ali z medicinskim osebjem na najbližjem oddelku nujne medicinske pomoči.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription. 
Druga zdravila in zdravilo Klopidogrel Mylan Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli zdravilo, tudi če ste ga dobili brez recepta.
In vitro studies have shown the increase in repaglinide exposure is due to inhibition of CYP2C8 by the glucuronide metabolite of clopidogrel. 
In vitro študije kažejo, da je povečana izpostavljenost repaglinida posledica zaviranja CYP2C8 z glukuronidnim presnovkom klopidogrela.
Heparins were administered in more than 90% of the patients and the relative rate of bleeding between clopidogrel and placebo was not significantly affected by the concomitant heparin therapy. 
Heparine so uporabljali pri več kot 90 % bolnikov, sočasna uporaba heparinske terapije ni pomembno vplivala na relativni delež krvavitev med klopidogrelom in placebom.
Clopidogrel significantly reduced the relative risk of death from any cause by 7% (p=0.029), and the relative risk of the combination of re-infarction, stroke or death by 9% (p=0.002), representing an absolute reduction of 0.5% and 0.9%, respectively. 
Klopidogrel je pomembno zmanjšal relativno tveganje za smrt zaradi kateregakoli vzroka za 7 % (p=0,029) in relativno tveganje za ponovni infarkt, kap ali smrt za 9 % (p=0,002), kar je predstavljalo absolutno zmanjšanje za 0,5 % oziroma 0,9 %.
• Paediatric population Clopidogrel should not be used in children because of efficacy concerns (see section 5.1). 
Klopidogrel naj se pri otrocih ne uporablja iz razlogov, ki zadevajo učinkovitost (glejte poglavje 5.1).
Thienopyridines may cause mild to severe allergic reactions such as rash, angioedema, or haematological cross-reactions such as thrombocytopaenia and neutropaenia. 
Tienopiridini lahko povzročijo blage do hude alergijske reakcije, na primer izpuščaj, angioedem ali hematološke navzkrižne reakcije, naprimer trombocitopenijo in nevtropenijo.
Patients randomized in the ACTIVE program were those presenting with documented AF, i.e., either permanent AF or at least 2 episodes of intermittent AF in the past 6 months, and had at least one of the following risk factors: age 75 years or age 55 to 74 years and either diabetes mellitus requiring drug therapy, or documented previous MI or documented coronary artery disease; treated for systemic hypertension; prior stroke, transient ischaemic attack (TIA), or non-CNS systemic embolus; left ventricular dysfunction with left ventricular ejection fraction <45%; or documented peripheral vascular disease. 
V program ACTIVE so bili randomizirani bolniki, ki so imeli dokumentirano AF, tj. bodisi permanentno AF ali vsaj 2 epizodi intermitentne AF v zadnjih 6 mesecih ter vsaj enega od naslednjih dejavnikov tveganja: starost  75 let ali starost od 55 do 74 let in bodisi sladkorno bolezen, ki je zahtevala zdravljenje z zdravili, ali dokumentiran predhodni MI ali dokumentirano koronarno bolezen; zdravljenje zaradi sistemske hipertenzije; predhodno možgansko kap, tranzitorno ishemično atako (TIA) ali sistemski embolus (ne v osrednjem živčevju); disfunkcijo levega prekata z iztisnim deležem levega prekata (LVEF) < 45 %; ali dokumentirano bolezen perifernih žil.
New cardiovascular events (primary endpoint) were prevented, with relative risk reductions of 22% (CI: 8.6, 33.4), 32% (CI: 12.8, 46.4), 4% (CI: -26.9, 26.7), 6% (CI: -33.5, 34.3) and 14% (CI: -31.6, 44.2), during the 0-1, 1-3, 3-6, 6-9 and 9-12 month study intervals, respectively. 
Nove srčnožilne dogodke (primarni opazovani dogodek) so preprečeli z zmanjšanjem relativnega tveganja: 22 % (IZ: 8,6, 33,4), 32 % (IZ: 12,8, 46,4), 4 % (IZ: -26,9, 26,7), 6 % (IZ: -33,5, 34,3) in 14 % (IZ: -31,6, 44,2) tekom 0-1, 1-3, 3-6, 6-9 oziroma 9-12 mesečnimi intrevali študije.
Elimination Following an oral dose of 
Eliminacija Po peroralnem odmerku s
Titanium dioxide (E171) Red iron oxide (E172) Yellow iron oxide (E172) Talc 
polivinilalkohol titanov dioksid (E171) rdeči železov oksid (E172) rumeni železov oksid (E172) smukec makrogol 3000 (polietilenglikol)
Week 2 (for boxes of 14, 28, 56, 84) Week 3 (for boxes of 28, 56, 84) Week 4 (for boxes of 28, 56, 84) 
Teden 2 (samo za škatle z 14, 28, 56 in 84 tabletami) Teden 3 (samo za škatle z 28, 56 in 84 tabletami) Teden 4 (samo za škatle z 28, 56 in 84 tabletami)
If you are pregnant or suspect that you are pregnant, you should tell your doctor or your pharmacist before taking Clopidogrel Mylan. 
Če ste noseči ali mislite, da ste noseči, morate o tem obvestiti zdravnika ali farmacevta, preden vzamete zdravilo Klopidogrel Mylan.
What Clopidogrel Mylan is and what it is used for 
Kaj je zdravilo Klopidogrel Mylan in za kaj ga uporabljamo
The recommended dose, including for patients with a condition called ‘atrial fibrillation' (an irregular heartbeat), is one 75 mg tablet of Clopidogrel Mylan per day to be taken orally with or without food, and at the same time each day. 
Priporočeni odmerek, vključno za bolnike, ki imajo bolezensko stanje, imenovano "atrijska fibrilacija" (nepravilen srčni utrip), je ena 75 mg tableta zdravila Klopidogrel Mylan na dan, ki jo lahko vzamete s hrano ali brez nje; odmerek morate jemati vsak dan ob istem času.
For the 7, 14, 28, 56, 84 tablets (calendar blister) pack sizes, you can check the day on which you last took a tablet of Clopidogrel Mylan by referring to the calendar printed on the blister 
Pri velikosti pakiranja po 7, 14, 28, 56 ali 84 tablet (v koledarskem pretisnem omotu) lahko po koledarju, ki je natisnjen na pretisnem omotu, preverite, na kateri dan v tednu ste nazadnje vzeli tableto zdravila Klopidogrel Mylan.
Follow-up at one year was performed for 316 patients (98.1%) in the de-escalated DAPT group and 318 patients (98.5%) in the unchanged DAPT group. 
Enoletno spremljanje je bilo opravljeno pri 316 bolnikih (98,1 %) v skupini z deeskaliranim DAPT in pri 318 bolnikih (98,5 %) v skupini z nespremenjenim DAPT.
What you need to know before you take Clopidogrel Mylan 3. 
Kaj morate vedeti, preden boste vzel zdravilo Klopidogrel Mylan 3.
Overall, clopidogrel 75 mg/day was comparable to ASA 325 mg/day in CAPRIE regardless of age, gender and race. 
V celoti je bil klopidogrel v odmerku 75 mg na dan v študiji CAPRIE, primerljiv z ASA v odmerku 325 mg na dan, ne glede na starost, spol ali raso.
The primary endpoint was the occurrence of the composite of an occluded infarct-related artery on the predischarge angiogram, or death or recurrent MI before coronary angiography. 
Primarni opazovani dogodki so bili navzočnost zamašene arterije (povezane z infarktom) na angiogramu pred odpustom ali smrt ali ponovni miokardni infarkt pred koronarno angiografijo.
For more than 12 hours: patients should take the next dose at the regular scheduled time and should not double the dose. 
če je zamuda več kot 12 ur: bolnik naj naslednji odmerek vzame ob pravem času; odmerka ne sme podvojiti.
A total of 99.7% of patients received fibrinolytics (fibrin specific: 68.7%, non-fibrin specific: 31.1%), 89.5% heparin, 78.7% beta blockers, 54.7% ACE inhibitors and 63% statins. 
Skupno 99,7 % bolnikov je dobivalo fibrinolitike (fibrinsko specifične: 68,7 %, nefebrinsko specifične: 31,1 %), 89,5 % heparin, 78,7 % zaviralce adrenergičnih receptorjev beta, 54,7 % zaviralce ACE in 63 % statine.
Medicinal products that are strong or moderate CYP2C19 inhibitors include, for example, omeprazole and esomeprazole, fluvoxamine, fluoxetine, moclobemide, voriconazole, fluconazole, ticlopidine, carbamazepine, and efavirenz. 
Med zdravila, ki so močni ali zmerni zaviralci CYP2C19, spadajo, na primer: omeprazol in esomeprazol, fluvoksamin, fluoksetin, moklobemid, vorikonazol, flukonazol, tiklopidin, karbamazepin in efavirenz.
The use of clopidogrel in CURE was associated with a decrease in the need of thrombolytic therapy (RRR = 43.3%; CI: 24.3%, 57.5%) and GPIIb/IIIa inhibitors (RRR = 18.2%; CI: 6.5%, 28.3%). 
Uporaba klopidogrela v CURE je bila povezana z zmanjšano potrebo po zdravljenju s trombolitiki (zmanjšanje RT= 43,3 %; IZ: 24,3 %, 57,5 %) in inhibitorji glikoproteinov IIb/IIIa (zmanjšanje RT =18,2 %; IZ: 6,5 %, 28,3 %).
• Adult patients suffering from acute coronary syndrome: - Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA). 
• Odraslih bolnikih z akutnim koronarnim sindromom: akutni koronarni sindrom brez elevacije ST spojnice (nestabilna angina ali miokardni infarkt brez Q zobca), vključno z bolniki, katerim je bil vstavljen stent po perkutani koronarni intervenciji, v kombinaciji z acetilsalicilno kislino (ASA).
• You should also tell your doctor immediately if you develop a medical condition (also known as Thrombotic Thrombocytopenic Purpura or TTP) that includes fever and bruising under the skin that may appear as red pinpoint dots, with or without unexplained extreme tiredness, confusion, yellowing of the skin or eyes (jaundice) (see section 4 ‘Possible side effects'). 
• morate takoj povedati zdravniku, če razvijete bolezensko stanje (znano tudi kot trombotična trombocitopenična purpura ali TTP) z zvišano telesno temperaturo in modricami pod kožo, ki se lahko pojavijo kot drobne rdeče pike, z ali brez nerazložljive hude utrujenosti, zmedenosti, porumenele kože ali oči (zlatenica) (glejte poglavje 4 »MOŽNI NEŽELENI UČINKI«);
Serum sickness, anaphylactoid reactions, cross-reactive drug hypersensitivity among thienopyridines (such as ticlopidine, prasugrel) (see section 4.4), insulin autoimmune syndrome, which can lead to severe hypoglycemia, particularly in patients with HLA DRA4 subtype (more frequent in the Japanese population)* 
Bolezni imunskega sistema serumska bolezen, anafilaktoidne reakcije, navzkrižna preobčutljivost med tienopiridini (kot sta tiklopidin in prasugrel) (glejte poglavje 4.4), avtoimuni inzulinski sindrom, ki lahko vodi v resno hipoglikemijo, še posebej pri bolnikih s HLA DRA4 podtipom (pogostejši v japonski populaciji)*
The major exclusion criteria for patients were documented peptic ulcer disease within the previous 6 months; prior intracerebral hemorrhage; significant thrombocytopenia (platelet count < 50 x 109/l); requirement for clopidogrel or oral anticoagulants (OAC); or intolerance to any of the two compounds. 
Glavna merila za nevključitev bolnikov so bila potrjena peptična ulkusna bolezen v preteklih 6 mesecih, predhodna intracerebralna krvavitev, pomembna trombocitopenija (število trombocitov < 50 x 109/l), potreba po klopidogrelu ali peroralnih antikoagulantih ali intoleranca za katero od obeh snovi.
If you have experienced severe chest pain (unstable angina or heart attack), your doctor may give you 300 mg of Clopidogrel Mylan (4 tablets of 75 mg) once at the start of treatment. 
Če ste imeli hudo bolečino v prsih (nestabilna angina pektoris ali srčna kap), vam lahko zdravnik na začetku zdravljenja predpiše 300 mg zdravila Klopidogrel Mylan (4 tablete po 75 mg).
This leaflet was last revised in MM/YYYY. 
Navodilo je bilo nazadnje revidirano dne <mesec//LLLL>
Clopidogrel Mylan contains clopidogrel and belongs to a group of medicines called antiplatelet medicinal products. 
Klopidogrel Mylan vsebuje klopidogrel in spada v skupino zdravil, ki se imenujejo zaviralci agregacije trombocitov.
Bullous dermatitis (toxic epidermal necrolysis, Stevens Johnson Syndrome, erythema multiforme, acute generalised exanthematous pustulosis (AGEP)), angioedema, drug induced hypersensitivity syndrome, drug rash with eosinophilia and systemic symptoms (DRESS), rash erythematous or exfoliative, urticaria, eczema, lichen planus 
bulozni dermatitis (toksična epidermalna nekroliza, StevensJohnsonov sindrom, multiformni eritem, akutna generalizirana eksantemska pustuloza (AGEP)), angioedem, z zdravili povzročen sindrom preobčutljivosti (sindrom DIHS, Drug-Induced Hypersensitivity Syndrome), kožni izpuščaj z eozinofilijo in sistemskimi simptomi, kot posledica zdravljenja z zdravilom (sindrom DRESS, Drug Rash with Eosinophilia and Systemic Symptoms), eritematozni ali eksfoliativni izpuščaj, urtikarija, ekcem, lihen planus
The other ingredients are: Tablet core: microcrystalline cellulose, colloidal anhydrous silica, crospovidone (type A), macrogol 6000, hydrogenated castor oil (see section 2 ‘Clopidogrel Mylan contains hydrogenated castor oil') Film-coating: polyvinyl alcohol, titanium dioxide (E171), red iron oxide (E172), yellow iron oxide (E172), talc and macrogol 3000. 
Pomožne snovi so: Jedro tablete: mikrokristalna celuloza, brezvodni koloidni silicijev dioksid, krospovidon (vrsta A), makrogol 6000 in hidrogenirano ricinusovo olje (glejte poglavje 2: »Zdravilo Klopidogrel Mylan vsebuje tudi hidrogenirano ricinusovo olje«) Obloga tablete: polivinilalkohol, titanov dioksid (E171), rdeči železov oksid (E172), rumeni železov oksid (E172), smukec in makrogol 3000.
MARKETING AUTHORISATION NUMBER(S) EU/1/09/559/001-016 
ŠTEVILKA (ŠTEVILKE) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/09/559/001-016
What you need to know before you take Clopidogrel Mylan 
Kaj morate vedeti, preden boste vzeli zdravilo Klopidogrel Mylan
LIST OF EXCIPIENTS It also contains hydrogenated castor oil. 
SEZNAM POMOŽNIH SNOVI Vsebuje hidrogenirano ricinusovo olje.
In patients with atrial fibrillation, clopidogrel should be given as a single daily dose of 75 mg. ASA (75 - 100 mg daily) should be initiated and continued in combination with clopidogrel (see section 
Bolniki z atrijsko fibrilacijo morajo klopidogrel dobivati v enkratem dnevnem odmerku 75 mg. ASA (75-100 mg na dan) je treba uvesti in nadaljevati v kombinaciji s klopidogrelom (glejte poglavje 5.1).
The dose of 0.2 mg/kg achieved the mean percent inhibition of 49.3% (5 µM ADP-induced platelet aggregation) which was comparable to that of adults taking clopidogrel 75 mg/day. 
Odmerek 0,2 mg/kg je dosegel povprečno 49,3 % zavrtje (agregacija trombocitov povzročena s 5 µM ADP), primerljivo kot pri odraslih ob uporabi zdravila klopidogrel v odmerku 75 mg/dan.
Clopidogrel Mylan contains hydrogenated castor oil This may cause stomach upset or diarrhoea. 
Zdravilo Klopidogrel Mylan vsebuje hidrogenirano ricinusovo olje To lahko povzroči želodčne motnje ali drisko.
Pregnancy and breast-feeding It is preferable not to take this medicine during pregnancy. 
Nosečnost in dojenje Priporočljivo je, da tega zdravila ne jemljejo nosečnice in matere, ki dojijo.
Boxes of 30x1 and 50x1 film-coated tablets in perforated unit dose blisters are available. 
Na voljo so škatle s 30 x 1 ali 50 x 1 filmsko obloženo tableto v perforiranem pretisnem omotu za posamično odmerjanje.
In ACTIVE A, the rate of major bleeding was greater in the clopidogrel + ASA group than in the placebo + ASA group (6.7% versus 4.3%). 
V študiji ACTIVE-A je bil delež hujših krvavitev v skupini s klopidogrelom + ASA večji kot v skupini s placebom + ASA (6,7 % v primerjavi s 4,3 %).
However, patients entered into clinical trials with clopidogrel received a variety of concomitant medicinal products including diuretics, beta blockers, ACEI, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions. 
Vendar pa so bolniki, ki so bili vključeni v klinično preskušanje klopidogrela, prejemali sočasno različna zdravila, tudi z diuretiki, zaviralci adrenergičnih receptorjev beta, zaviralci angiotenzinske konvertaze (ACEI), kalcijevimi antagonisti, učinkovinami za zniževanje holesterola, koronarnimi vazodilatatorji, antidiabetiki (vključno z insulinom), antiepileptičnimi učinkovinami in antagoniste glikoproteina IIb/IIIa, brez dokazov o klinično pomembnih neželenih interakcijah.
- ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy. 
akutni miokardni infarkt z elevacijo ST spojnice v kombinaciji z ASA pri bolnikih, ki se zdravijo z zdravili in so primerni za trombolitično zdravljenje.
INFORMATION IN BRAILLE Clopidogrel Mylan 75 mg 
Klopidogrel Mylan 75 mg
In particular, in a post-hoc analysis in 2,172 patients (17% of the total CURE population) who underwent stent placement (Stent-CURE), the data showed that clopidogrel compared to placebo, demonstrated a significant RRR of 26.2% favouring clopidogrel for the co-primary endpoint (CV death, MI, stroke) and also a significant RRR of 23.9% for the second co-primary endpoint (CV death, MI, stroke or refractory ischaemia). 
Zlasti post hoc analiza podatkov 2172 bolnikov (17 % celotne populacije CURE), ki so jim namestili žilno opornico (Stent-CURE), je ob klopidogrelu v primerjavi s placebom pokazala značilno, 26,2 % zmanjšanje RT za sestavljen primarni opazovani dogodek (srčno žilna smrt, miokardni infarkt, možganska kap) in tudi značilno, 23,9 % zmanjšanje RT za drugsestavljen primarni opazovani dogodek (srčno-žilna smrt, miokardni infarkt, možganska kap ali neodzivna ishemija).